Chugai Pharmaceutical at Antibody Engineering 2026
Dec 13–16, 2026 San Diego, CA ~900 attendees Website
Chugai Pharmaceutical takes part in 2 sessions at Antibody Engineering 2026 in San Diego. Its program centers on antibody designs that control when a drug becomes active and how long it lasts. One keeps the immune signal IL-12 masked until a protease releases it, and another is a longer-lasting antibody against an inactive form of TGF-beta1 for fibrotic diseases.
| Organization | Antibody Engineering 2026 Attendance |
|---|---|
Chugai Pharmaceutical Tokyo, Japan | |
Japanese pharmaceutical company and Roche Group member known for antibody engineering technologies such as recycling and bispecific antibodies. | Talk Mon Dec 14 3:30pm–4:00pm Protease-Activated IL-12 Masking via Engineered VH Dissociation and IL-12 Intrinsic activity Enables Tunable Cytokine Activation Caging a powerful immune-signaling protein so it only switches on where tumor enzymes cut the cage open. Talk Tue Dec 15 4:45pm–5:15pm Long Acting Anti-latent TGF-β1 Recycling Antibody for Fibrotic Diseases An antibody that is recycled back out of cells, letting it block a scarring-driving growth factor for far longer. Protein engineering |
Find decision makers at Chugai Pharmaceutical
Tell us what you sell and we’ll find the people at Chugai Pharmaceutical most likely to buy it.
- Who to contact
- Their contact info
- What to say
- Free, no sign-up
Not affiliated with or endorsed by Antibody Engineering & Therapeutics, its organizers or The Antibody Society. Submit a correction